PainChek Ltd ( (AU:PCK) ) just unveiled an update.
PainChek Ltd has received a $1.41 million R&D tax refund for FY24, which, along with recent capital raising, will support the completion of key milestones. The company is advancing its US FDA review for the PainChek Adult App, with regulatory clearance anticipated in the first half of 2025, potentially opening a $100 million per annum market in US aged care. Additionally, PainChek has launched its Infant App on the Apple App Store in Australia, receiving positive feedback from parents for its ease of use and effectiveness. The company plans a broader marketing rollout in Q2 2025, supported by strategic partnerships and user insights.
More about PainChek Ltd
PainChek Ltd is a company that develops smart device-based pain assessment and monitoring applications. It operates in the healthcare industry, focusing on providing solutions for pain management through its AI-driven technology. The company’s products are designed to assist individuals who cannot reliably self-report their pain, offering a unique tool for both patients and healthcare providers.
YTD Price Performance: 10.0%
Average Trading Volume: 1,068,923
Technical Sentiment Signal: Buy
Current Market Cap: A$60.78M
See more insights into PCK stock on TipRanks’ Stock Analysis page.